Spots Global Cancer Trial Database for gsk1120212
Every month we try and update this database with for gsk1120212 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors | NCT01231594 | Cancer | GSK2118436 GSK1120212 Other approved ... | 18 Years - | Novartis | |
| Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | NCT01328106 | GNA11 Mutation-... GNAQ Mutation-p... Cancer Metastatic Uvea... | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias | NCT00920140 | Cancer | GSK1120212 GSK1120212 | 18 Years - | GlaxoSmithKline | |
| A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 | NCT01658553 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 | NCT01467310 | Breast Cancer | GSK1120212 | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer | NCT01553851 | Neoplasms, Oral Mouth Neoplasms | GSK1120212 | 18 Years - | Washington University School of Medicine | |
| Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | NCT00687622 | Solid Tumours | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Absolute Bioavialability of GSK1120212 | NCT01416337 | Cancer | GSK1120212 GSK1120212B | 18 Years - | GlaxoSmithKline | |
| Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | NCT01192165 | Cancer | Trametinib (GSK... Docetaxel Erlotinib Pemetrexed Carboplatin nab-Paclitaxel Cisplatin | 18 Years - | GlaxoSmithKline | |
| Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors | NCT01428427 | Leukaemia, Myel... | GSK1120212 Gemcitabine | 18 Years - | GlaxoSmithKline | |
| An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | NCT01619774 | Melanoma | GSK2118436 GSK1120212 | 16 Years - | M.D. Anderson Cancer Center | |
| GSK1120212 Food-effect Study | NCT01371487 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies | NCT01725100 | Cancer | GSK1120212B (St... GSK1120212B (Lo... | 18 Years - | GlaxoSmithKline | |
| Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | NCT00687622 | Solid Tumours | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias | NCT00920140 | Cancer | GSK1120212 GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 | NCT01387204 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | NCT01336634 | Cancer | Dabrafenib Trametinib | 18 Years - | Novartis | |
| GSK1120212 Rollover Study | NCT01376310 | Cancer | GSK1120212 Docetaxel + GSK... Erlotinib + GSK... Pemetrexed + GS... Carboplatin + G... Nab-paclitaxel ... Gemcitabine + G... Everolimus + GS... | 18 Years - | Novartis | |
| Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175 | Cancer | GSK2118436 GSK1120212 | 18 Years - | Novartis | |
| GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma | NCT01245062 | Melanoma | GSK1120212 Chemotherapy | 18 Years - | GlaxoSmithKline | |
| Safety, Pharmacokinetics (PK) of AKT and MEK Combination | NCT01138085 | Cancer | GSK1120212 GSK2141795 | 18 Years - | GlaxoSmithKline | |
| Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | NCT01336634 | Cancer | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | NCT00687622 | Solid Tumours | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients | NCT01155453 | Advanced and Se... | BKM120 GSK1120212 | 18 Years - | Novartis | |
| Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 | NCT01387204 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 | NCT01387204 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors | NCT01324258 | Solid Tumours | GSK1120212 Gemcitabine | 20 Years - | GlaxoSmithKline | |
| Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | NCT01328106 | GNA11 Mutation-... GNAQ Mutation-p... Cancer Metastatic Uvea... | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers | NCT01476137 | Cancer | GSK1120212 GSK2110183 | 18 Years - | GlaxoSmithKline | |
| Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors | NCT01324258 | Solid Tumours | GSK1120212 Gemcitabine | 20 Years - | GlaxoSmithKline | |
| Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer | NCT03428126 | Malignant Neopl... Colorectal Canc... Colon Cancer | Durvalumab Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor | NCT01037127 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
